Cytori Cell Research Institute,Inc. Logo

Cytori Cell Research Institute,Inc.

Develops devices and cell therapies using a patient's fat tissue to repair injury and treat disease.

3750 | T

Overview

Corporate Details

ISIN(s):
JP3426500009
LEI:
Country:
Japan
Address:
千代田区麹町2丁目3番3号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cytori Cell Research Institute, Inc., now operating as ADR120S, Inc., is a regenerative medicine company focused on developing novel cell therapies. The company engages in the research, development, production, and sale of medical devices and related kits for cell-based treatments. Its core technology centers on a proprietary system to extract and concentrate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue. These therapies are designed to repair injured tissue, preserve function, and address various diseases with unmet medical needs, such as osteoarthritis and diabetic foot lesions. The company aims to provide safe and effective treatment options by harnessing the potential of cellular therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 08:04
Registration Form
確認書
Japanese 8.6 KB
2025-11-14 08:03
Interim / Quarterly Report
半期報告書-第22期(2025/04/01-2026/03/31)
Japanese 194.2 KB
2025-11-07 07:42
Registration Form
確認書
Japanese 8.3 KB
2025-11-07 07:39
Annual Report
訂正有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 597.9 KB
2025-07-01 04:31
AGM Information
臨時報告書
Japanese 24.3 KB
2025-06-27 09:17
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 09:16
Annual Report
有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 946.5 KB
2025-06-27 09:16
Governance Information
内部統制報告書-第21期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-05-30 02:01
Regulatory Filings
臨時報告書
Japanese 20.1 KB
2025-02-10 08:41
AGM Information
臨時報告書
Japanese 20.5 KB
2025-01-06 08:19
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-11-14 08:06
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 08:05
Interim / Quarterly Report
半期報告書-第21期(2024/04/01-2025/03/31)
Japanese 190.1 KB
2024-09-24 09:07
M&A Activity
臨時報告書
Japanese 19.8 KB
2024-07-29 08:30
Major Shareholding Notification
臨時報告書
Japanese 21.5 KB

Automate Your Workflow. Get a real-time feed of all Cytori Cell Research Institute,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cytori Cell Research Institute,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cytori Cell Research Institute,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bone Biologics Corp Logo
Developing a protein-based bone graft for targeted bone regeneration in spinal fusion.
United States of America
BBLG
Bonyf N.V. Logo
Develops patented oral, dental, and dermatological care products for consumers and professionals.
Belgium
MLBON
Boryung Corporation Logo
South Korea
003850
Bosnalijek d.d. Sarajevo Logo
Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.
Bosnia and Herzegovina
BSNL
Boule Diagnostics Logo
Global provider of complete hematology systems for human and veterinary diagnostics.
Sweden
BOUL
Boundless Bio, Inc. Logo
Developing ecDNA-directed therapies for intractable oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and genetically driven cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.
United States of America
DRUG
Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.
Japan
4594

Talk to a Data Expert

Have a question? We'll get back to you promptly.